MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 10/27/2018 |
| Start Date: | August 24, 2018 |
| End Date: | December 30, 2023 |
| Contact: | Sharanya Chandrasekhar, M.S. |
| Email: | shc2043@med.cornell.edu |
| Phone: | 646-962-2196 |
Prostate SBRT is a standard of care treatment for prostate cancer that has not spread to
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.
Prostate SBRT is a standard of care treatment for prostate cancer that has not spread to
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.
Hypothesis: MRI-guided treatment planning and delivery can selectively target high-risk
prostate nodules and deliver a higher radiation dose, to achieve maximal local control
without increasing treatment toxicity
distant metastatic sites. Radiation is delivered to the prostate and seminal vesicles in 5
treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated
good outcomes with acceptable toxicity. In this initial study, MRI guided treatment planning
and delivery will be used to deliver 7 Gy to the entire prostate and seminal vesicles, with a
selective boost of additional 0.5, 1.0, 1.5 or 2 Gy per fraction for total dose of 37.5, 40,
42.5 or 45 Gy to biopsy proven lesions, defined using MRI.
Hypothesis: MRI-guided treatment planning and delivery can selectively target high-risk
prostate nodules and deliver a higher radiation dose, to achieve maximal local control
without increasing treatment toxicity
Inclusion Criteria:
- Biopsy-proven diagnosis of prostate adenocarcinoma
- NCCN defined low-, intermediate- and high-risk prostate cancer
- Age ≥ 18
- Patient must have prostate MRI with a PIRADS 4 or 5 lesion
Exclusion Criteria:
- History of prior pelvic radiation (external beam or brachytherapy)
- History of TURP
- Inability to undergo MRI
- Patients with metastatic disease (other than pelvic lymph nodes) are ineligible for
this study
- AUA score >17
We found this trial at
1
site
New York, New York 10065
Principal Investigator: Josephine Kang, M.D.
Phone: 646-962-2196
Click here to add this to my saved trials
